indomethacin has been researched along with Intestinal Perforation in 64 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Intestinal Perforation: Opening or penetration through the wall of the INTESTINES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if intestinal perforations before 14 days (either spontaneous (SIP) or necrotizing enterocolitis-induced) are increased when infants who received antenatal betamethasone shortly before birth are treated with prophylactic indomethacin (PINDO)." | 8.31 | Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation. ( Clyman, RI; Hills, NK, 2023) |
| "To estimate if the odds of spontaneous intestinal perforation (SIP) are increased when antenatal steroids (ANS) given close to delivery are combined with indomethacin on day 1 after birth (Indo-D1)." | 8.31 | Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation. ( Arnautovic, TI; Brion, LP; Chowdhury, D; Das, A; Keszler, M; Laptook, AR; Oh, W; Weydig, H; Wyckoff, MH; Younge, N, 2023) |
| "To determine if antenatal variables affect the risk of spontaneous intestinal perforation (SIP) among preterm infants when prophylactic indomethacin is used." | 8.02 | Antenatal Risk Factors Associated with Spontaneous Intestinal Perforation in Preterm Infants Receiving Postnatal Indomethacin. ( Arnautovic, TI; Keszler, M; Laptook, AR; Longo, JL; Trail-Burns, EJ; Tucker, R, 2021) |
| "To evaluate the association of a combined exposure to antenatal steroids and prophylactic indomethacin with the outcome of spontaneous intestinal perforation (SIP) among neonates born at <26 weeks of gestation or <750 g birth weight." | 8.02 | Association of Co-Exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation. ( Adie, MA; Daspal, S; Dorling, J; Kandraju, H; Kanungo, J; Lee, KS; Lee, SK; Shah, PS; Ye, XY, 2021) |
| "To determine the effect of concomitant administration of prophylactic indomethacin and early enteral feeds on the risk of spontaneous intestinal perforation (SIP) in extremely low-birth-weight (ELBW) infants, and to describe the variation in prophylactic indomethacin use in Canada." | 7.85 | Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants. ( Cieslak, Z; Claveau, M; Shah, PS; Sherlock, R; Stavel, M; Wong, J, 2017) |
| "Prophylactic indomethacin reduces severe intraventricular hemorrhage but may increase spontaneous intestinal perforation (SIP) in extremely low birth weight (ELBW) infants." | 7.80 | Prophylactic indomethacin and intestinal perforation in extremely low birth weight infants. ( Ambalavanan, N; Ball, MB; Bell, EF; Bhat, R; Carlo, WA; Das, A; Hale, EC; Higgins, RD; Kelleher, J; Laptook, AR; Newman, NS; Peralta-Carcelen, M; Saha, S; Salas, AA; Sánchez, PJ; Shankaran, S; Stoll, BJ; VanMeurs, KP; Walsh, MC, 2014) |
| "Early postnatal steroids and indomethacin in combination have been shown to increase the risk of spontaneous intestinal perforation (SIP) in infants with extremely low birth weight (ELBW), but the mechanism behind this synergistic effect is unknown." | 7.74 | A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin. ( Aschner, JL; Gaston, BM; Gordon, PV; Herman, AC; Laubach, VE; Marcinkiewicz, M, 2007) |
| "Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 7.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 7.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| "Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 7.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
| "Four very-low-birth-weight infants developed localized intestinal perforations after enteral administration of indomethacin." | 7.67 | Localized intestinal perforations after enteral administration of indomethacin in premature infants. ( Alpan, G; Amir, G; Eyal, F; Glick, B; Mogle, P; Udassin, R; Vinograd, I, 1985) |
| "This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 7.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
| "Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 5.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
| "Three preterm infants exposed antenatally to indomethacin developed a characteristic syndrome consisting of edema and hydrops with a bleeding disorder at birth, oliguric renal failure during the first 3 postnatal days, and acute pneumoperitoneum resulting from localized ileal perforation(s) at the end of the first week of life." | 4.77 | Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. ( Coppens, M; Cuvelier, C; de Praeter, C; Dhont, M; Govaert, P; Leroy, JG; Thiery, M; Vanhaesebrouck, P, 1988) |
| "To determine if intestinal perforations before 14 days (either spontaneous (SIP) or necrotizing enterocolitis-induced) are increased when infants who received antenatal betamethasone shortly before birth are treated with prophylactic indomethacin (PINDO)." | 4.31 | Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation. ( Clyman, RI; Hills, NK, 2023) |
| "To estimate if the odds of spontaneous intestinal perforation (SIP) are increased when antenatal steroids (ANS) given close to delivery are combined with indomethacin on day 1 after birth (Indo-D1)." | 4.31 | Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation. ( Arnautovic, TI; Brion, LP; Chowdhury, D; Das, A; Keszler, M; Laptook, AR; Oh, W; Weydig, H; Wyckoff, MH; Younge, N, 2023) |
| " Early indomethacin was associated with a lower risk of patent ductus arteriosus and bronchopulmonary dysplasia and a higher risk of spontaneous intestinal perforation." | 4.12 | Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants. ( Ambalavanan, N; Bell, EF; Carlo, WA; Chawla, S; Chowdhury, D; Das, A; Gantz, M; Harmon, HM; Laptook, AR; Natarajan, G; Shankaran, S; Tapia, JL, 2022) |
| "To determine if antenatal variables affect the risk of spontaneous intestinal perforation (SIP) among preterm infants when prophylactic indomethacin is used." | 4.02 | Antenatal Risk Factors Associated with Spontaneous Intestinal Perforation in Preterm Infants Receiving Postnatal Indomethacin. ( Arnautovic, TI; Keszler, M; Laptook, AR; Longo, JL; Trail-Burns, EJ; Tucker, R, 2021) |
| "To evaluate the association of a combined exposure to antenatal steroids and prophylactic indomethacin with the outcome of spontaneous intestinal perforation (SIP) among neonates born at <26 weeks of gestation or <750 g birth weight." | 4.02 | Association of Co-Exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation. ( Adie, MA; Daspal, S; Dorling, J; Kandraju, H; Kanungo, J; Lee, KS; Lee, SK; Shah, PS; Ye, XY, 2021) |
| "To evaluate the impact of prophylactic indomethacin on early death (<10 days after birth) or severe neurologic injury and on early death or spontaneous intestinal perforation by completed weeks of gestational age in neonates born <29 weeks of gestation." | 4.02 | Gestational Age-Dependent Variations in Effects of Prophylactic Indomethacin on Brain Injury and Intestinal Injury. ( Abdelgadir, D; Afifi, J; Aziz, K; Crossman, SC; Mohammad, K; Piedboeuf, B; Qureshi, M; Shah, PS; Taylor, B; Ye, XY; Yuen, R, 2021) |
| "To determine the effect of concomitant administration of prophylactic indomethacin and early enteral feeds on the risk of spontaneous intestinal perforation (SIP) in extremely low-birth-weight (ELBW) infants, and to describe the variation in prophylactic indomethacin use in Canada." | 3.85 | Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants. ( Cieslak, Z; Claveau, M; Shah, PS; Sherlock, R; Stavel, M; Wong, J, 2017) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| "Diet, indomethacin, and early use of dexamethasone have been implicated as possible causes of necrotizing enterocolitis and intestinal perforation." | 3.74 | Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. ( Achanti, B; Lilien, L; Mehta, SK; Pietz, J; Stepka, EC, 2007) |
| "Early postnatal steroids and indomethacin in combination have been shown to increase the risk of spontaneous intestinal perforation (SIP) in infants with extremely low birth weight (ELBW), but the mechanism behind this synergistic effect is unknown." | 3.74 | A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin. ( Aschner, JL; Gaston, BM; Gordon, PV; Herman, AC; Laubach, VE; Marcinkiewicz, M, 2007) |
| "Spontaneous intestinal perforation (SIP) is increasingly common in the premature infant and has been demonstrated to be associated with early postnatal administration of glucocorticoids and indomethacin." | 3.73 | New insights into spontaneous intestinal perforation using a national data set: (2) two populations of patients with perforations. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
| "Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 3.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
| "To examine whether antenatal steroids (ANS), alone or with early indomethacin, are associated with spontaneous intestinal perforation (SIP)." | 3.73 | New insights into spontaneous intestinal perforation using a national data set (3): antenatal steroids have no adverse association with spontaneous intestinal perforation. ( Attridge, JT; Clark, R; Gordon, PV, 2006) |
| "A prematurely born girl presented with abdominal distension, bilious vomiting and a football sign on a plain abdominal X-ray, due to accumulation of free gas following infarction and perforation of the ileum: a complication of indomethacine." | 3.73 | [Diagnostic image (232). A neonate with bilious vomiting]. ( de Vries, A; van Rijn, RR, 2005) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 3.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| "This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 3.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
| "Four very-low-birth-weight infants developed localized intestinal perforations after enteral administration of indomethacin." | 3.67 | Localized intestinal perforations after enteral administration of indomethacin in premature infants. ( Alpan, G; Amir, G; Eyal, F; Glick, B; Mogle, P; Udassin, R; Vinograd, I, 1985) |
| "Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 3.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
| "Management of persistently patent ductus arteriosus (PDA) in extremely low-birth-weight infants (ELBWIs) requires attention due to the risk of tissue hypoperfusion." | 1.91 | Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience. ( Ibara, S; Ieiri, S; Ikee, T; Ikoma, S; Kawano, M; Kawano, T; Machigashira, S; Masuya, R; Matsukubo, M; Murakami, M; Muto, M; Nakame, K; Noguchi, H; Sugita, K; Torikai, M, 2023) |
| "Polyhydramnios was detected and the chloride level of the amniotic fluid was high." | 1.35 | Indomethacin-induced colon perforation in Bartter's syndrome. ( Ataoglu, E; Civilibal, M; Murat, E; Oktay, ER; Ozkul, AA; Varal, IG, 2009) |
| "Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 1.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
| "Isolated intestinal perforation has been described in premature neonates who were treated with indomethacin for patent ductus arteriosus." | 1.29 | Isolated small bowel perforation following intrauterine treatment with indomethacin. ( Bidiwala, KS; Delpino, ML; Fejgin, MD, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (25.00) | 18.7374 |
| 1990's | 6 (9.38) | 18.2507 |
| 2000's | 23 (35.94) | 29.6817 |
| 2010's | 11 (17.19) | 24.3611 |
| 2020's | 8 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chawla, S | 1 |
| Natarajan, G | 1 |
| Laptook, AR | 4 |
| Chowdhury, D | 2 |
| Bell, EF | 3 |
| Ambalavanan, N | 2 |
| Carlo, WA | 3 |
| Gantz, M | 1 |
| Das, A | 4 |
| Tapia, JL | 1 |
| Harmon, HM | 1 |
| Shankaran, S | 4 |
| Muto, M | 1 |
| Sugita, K | 1 |
| Murakami, M | 1 |
| Ikoma, S | 1 |
| Kawano, M | 1 |
| Masuya, R | 1 |
| Matsukubo, M | 1 |
| Kawano, T | 1 |
| Machigashira, S | 1 |
| Nakame, K | 1 |
| Torikai, M | 1 |
| Ikee, T | 1 |
| Noguchi, H | 1 |
| Ibara, S | 1 |
| Ieiri, S | 1 |
| Clyman, RI | 1 |
| Hills, NK | 1 |
| Weydig, H | 1 |
| Brion, LP | 1 |
| Wyckoff, MH | 1 |
| Arnautovic, TI | 2 |
| Younge, N | 1 |
| Oh, W | 3 |
| Keszler, M | 2 |
| AlRyalat, SA | 1 |
| Al Oweidat, K | 1 |
| Al-Amer, A | 1 |
| Khader, A | 1 |
| Ajaj, A | 1 |
| Alessa, Z | 1 |
| Roto, A | 1 |
| Longo, JL | 1 |
| Trail-Burns, EJ | 1 |
| Tucker, R | 1 |
| Qureshi, M | 1 |
| Shah, PS | 3 |
| Abdelgadir, D | 1 |
| Ye, XY | 2 |
| Afifi, J | 1 |
| Yuen, R | 1 |
| Crossman, SC | 1 |
| Taylor, B | 1 |
| Mohammad, K | 1 |
| Piedboeuf, B | 1 |
| Aziz, K | 1 |
| Kandraju, H | 1 |
| Kanungo, J | 1 |
| Lee, KS | 1 |
| Daspal, S | 1 |
| Adie, MA | 1 |
| Dorling, J | 1 |
| Lee, SK | 1 |
| Singh, M | 1 |
| Reichert, P | 1 |
| Cann, H | 1 |
| Chan, NM | 1 |
| Law, CW | 1 |
| Kwan, KF | 1 |
| McElroy, SJ | 1 |
| Kelleher, J | 1 |
| Salas, AA | 1 |
| Bhat, R | 1 |
| Saha, S | 3 |
| Stoll, BJ | 3 |
| Walsh, MC | 2 |
| Sánchez, PJ | 1 |
| VanMeurs, KP | 1 |
| Hale, EC | 1 |
| Newman, NS | 1 |
| Ball, MB | 1 |
| Higgins, RD | 1 |
| Peralta-Carcelen, M | 1 |
| Chen, Y | 1 |
| Chang, KT | 1 |
| Lian, DW | 1 |
| Lu, H | 1 |
| Roy, S | 1 |
| Laksmi, NK | 1 |
| Low, Y | 1 |
| Krishnaswamy, G | 1 |
| Pierro, A | 1 |
| Ong, CC | 1 |
| Stavel, M | 1 |
| Wong, J | 1 |
| Cieslak, Z | 1 |
| Sherlock, R | 1 |
| Claveau, M | 1 |
| Gordon, PV | 9 |
| Swanson, JR | 1 |
| Clark, R | 4 |
| Attridge, JT | 4 |
| Ataoglu, E | 1 |
| Civilibal, M | 1 |
| Ozkul, AA | 1 |
| Varal, IG | 1 |
| Oktay, ER | 1 |
| Murat, E | 1 |
| Sharma, R | 1 |
| Hudak, ML | 1 |
| Tepas, JJ | 1 |
| Wludyka, PS | 1 |
| Teng, RJ | 1 |
| Hastings, LK | 1 |
| Renfro, WH | 1 |
| Marvin, WJ | 1 |
| Loh, AH | 1 |
| Ong, LY | 1 |
| Liew, WK | 1 |
| Arkachaisri, T | 1 |
| Lee, VK | 1 |
| Narasimhan, KL | 1 |
| Jacobsen, AS | 1 |
| Wadhawan, R | 1 |
| Vohr, BR | 1 |
| Laptook, A | 1 |
| Higgins, R | 1 |
| Davis, JS | 1 |
| Ryan, ML | 1 |
| Shields, JM | 1 |
| Sola, JE | 1 |
| Perez, EA | 1 |
| Neville, HL | 1 |
| Rodriguez, MM | 1 |
| Sivanandan, S | 1 |
| Bali, V | 1 |
| Soraisham, AS | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Little, DC | 1 |
| Pratt, TC | 1 |
| Blalock, SE | 1 |
| Krauss, DR | 1 |
| Cooney, DR | 1 |
| Custer, MD | 1 |
| Hwang, H | 1 |
| Murphy, JJ | 1 |
| Gow, KW | 1 |
| Magee, JF | 1 |
| Bekhit, E | 1 |
| Jamieson, D | 1 |
| O'Donovan, DJ | 1 |
| Baetiong, A | 1 |
| Adams, K | 1 |
| Chen, A | 1 |
| Smith, EO | 1 |
| Adams, JM | 1 |
| Weisman, LE | 1 |
| Baldonedo Cernuda, RF | 1 |
| Alvarez Pérez, JA | 1 |
| García Bear, I | 1 |
| Truán Alonso, N | 1 |
| Jorge Barreiro, JI | 1 |
| Kocheril, SV | 1 |
| Blaivas, M | 1 |
| Appleton, BE | 1 |
| McCune, WJ | 1 |
| Ike, RW | 1 |
| de Vries, A | 1 |
| van Rijn, RR | 1 |
| Walker, MW | 2 |
| Bloom, BT | 1 |
| Paquette, L | 1 |
| Friedlich, P | 1 |
| Ramanathan, R | 1 |
| Seri, I | 1 |
| Pietz, J | 1 |
| Achanti, B | 1 |
| Lilien, L | 1 |
| Stepka, EC | 1 |
| Mehta, SK | 1 |
| Kawase, Y | 1 |
| Ishii, T | 1 |
| Arai, H | 1 |
| Uga, N | 1 |
| Herman, AC | 1 |
| Marcinkiewicz, M | 1 |
| Gaston, BM | 1 |
| Laubach, VE | 1 |
| Aschner, JL | 1 |
| Madan, J | 1 |
| Fiascone, J | 1 |
| Balasubramanian, V | 1 |
| Griffith, J | 1 |
| Hagadorn, JI | 1 |
| Day, TK | 1 |
| Calin, A | 1 |
| Nagaraj, HS | 1 |
| Sandhu, AS | 1 |
| Cook, LN | 1 |
| Buchino, JJ | 1 |
| Groff, DB | 1 |
| Lu, YF | 1 |
| Mizutani, M | 1 |
| Neya, T | 1 |
| Nakayama, S | 1 |
| Fejgin, MD | 1 |
| Delpino, ML | 1 |
| Bidiwala, KS | 1 |
| Going, JJ | 1 |
| Canvin, J | 1 |
| Sturrock, R | 1 |
| Shorter, NA | 1 |
| Liu, JY | 1 |
| Mooney, DP | 1 |
| Harmon, BJ | 1 |
| Gordon, P | 1 |
| Rutledge, J | 1 |
| Sawin, R | 1 |
| Thomas, S | 1 |
| Woodrum, D | 1 |
| Stark, AR | 1 |
| Tyson, JE | 1 |
| Papile, LA | 1 |
| Wright, LL | 1 |
| Donovan, EF | 1 |
| Bauer, CR | 1 |
| Poole, WK | 1 |
| Forshaw, MJ | 1 |
| Zayyan, K | 1 |
| Power, DM | 1 |
| Coutrot, S | 1 |
| Roland, D | 1 |
| Barbier, J | 1 |
| Van Der Marcq, P | 1 |
| Alcalay, M | 1 |
| Matuchansky, C | 1 |
| Crawshaw, A | 1 |
| Wolf, WM | 1 |
| Snover, DC | 1 |
| Leonard, AS | 1 |
| Vanhaesebrouck, P | 1 |
| Thiery, M | 1 |
| Leroy, JG | 1 |
| Govaert, P | 1 |
| de Praeter, C | 1 |
| Coppens, M | 1 |
| Cuvelier, C | 1 |
| Dhont, M | 1 |
| Hervás, JA | 1 |
| Masip, MC | 1 |
| Alomar, A | 1 |
| Bregante, JI | 1 |
| Marshall, TA | 1 |
| Pai, S | 1 |
| Reddy, PP | 1 |
| Kühl, G | 2 |
| Seyberth, HW | 2 |
| Alpan, G | 1 |
| Eyal, F | 1 |
| Vinograd, I | 1 |
| Udassin, R | 1 |
| Amir, G | 1 |
| Mogle, P | 1 |
| Glick, B | 1 |
| Wille, L | 1 |
| Bolkenius, M | 1 |
| Laidler, P | 1 |
| Maslin, SC | 1 |
| Gilhome, RW | 1 |
| Komatsu, T | 1 |
| Awata, H | 1 |
| Sakai, Y | 1 |
| Inukai, T | 1 |
| Kimura, M | 1 |
| Inaba, S | 1 |
| Yamamoto, H | 1 |
| Brodie, DA | 1 |
| Cook, PG | 1 |
| Bauer, BJ | 1 |
| Dagle, GE | 1 |
| Shack, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RIC-NEC Phase II Feasibility Randomized Controlled Trial: Remote Ischemic Conditioning in Necrotizing Enterocolitis[NCT05279664] | Phase 2 | 78 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Intestinal Function in Neonates With Complex Congenital Heart Disease[NCT01475357] | 27 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants[NCT00005777] | Phase 3 | 220 participants (Actual) | Interventional | 1998-02-28 | Terminated (stopped due to The trial was halted because of unanticipated nonrespiratory adverse events related to dexamethasone therapy.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for indomethacin and Intestinal Perforation
| Article | Year |
|---|---|
Understanding intestinal vulnerability to perforation in the extremely low birth weight infant.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Communicable Diseases; Disease Models, Animal; Fem | 2009 |
Understanding clinical literature relevant to spontaneous intestinal perforations.
Topics: Acute Disease; Bacterial Infections; Critical Care; Dexamethasone; Drug Therapy, Combination; Female | 2009 |
Segmental absence of intestinal musculature: an increasingly reported pathology.
Topics: Abdomen, Acute; Abnormalities, Multiple; Adult; Cesarean Section; Digestive System Abnormalities; Du | 2012 |
Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Female; Gestational Age; Hemorrhage; Humans; Indomethacin; Infant, Newbor | 2003 |
Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin.
Topics: Amniotic Fluid; Female; Gastrointestinal Hemorrhage; Humans; Ileal Diseases; Indomethacin; Infant, L | 1988 |
1 trial available for indomethacin and Intestinal Perforation
| Article | Year |
|---|---|
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Dexamethasone; D | 2001 |
58 other studies available for indomethacin and Intestinal Perforation
| Article | Year |
|---|---|
Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants.
Topics: Bronchopulmonary Dysplasia; Child; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; | 2022 |
Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience.
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indomethacin; Infant, Extr | 2023 |
Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation.
Topics: Betamethasone; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant; Infant, Newborn; In | 2023 |
Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation.
Topics: Adult; Birth Weight; Female; Gestational Age; Humans; Indomethacin; Infant; Infant, Newborn; Intesti | 2023 |
Perinatal events predicting retinopathy of prematurity in extremely pre-term infants.
Topics: Birth Weight; Cardiovascular Agents; Cellulitis; Cerebrospinal Fluid Shunts; Continuous Positive Air | 2020 |
Antenatal Risk Factors Associated with Spontaneous Intestinal Perforation in Preterm Infants Receiving Postnatal Indomethacin.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Case-Control Studi | 2021 |
Gestational Age-Dependent Variations in Effects of Prophylactic Indomethacin on Brain Injury and Intestinal Injury.
Topics: Brain Injuries; Canada; Female; Gestational Age; Humans; Indomethacin; Infant; Infant, Extremely Pre | 2021 |
Association of Co-Exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation.
Topics: Brain Injuries; Canada; Female; Gestational Age; Humans; Indomethacin; Infant; Infant, Newborn; Infa | 2021 |
Abrupt onset of abdominal pain. Duodenal perforation caused by indomethacin.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Diseases; Humans; Indomethacin; In | 2013 |
Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications.
Topics: Bronchopulmonary Dysplasia; Creatinine; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2014 |
Unraveling the enigma that is neonatal necrotizing enterocolitis.
Topics: Bacterial Infections; Dexamethasone; Female; Humans; Indomethacin; Infant, Very Low Birth Weight; In | 2014 |
Prophylactic indomethacin and intestinal perforation in extremely low birth weight infants.
Topics: Cohort Studies; Female; Follow-Up Studies; Humans; Indomethacin; Infant, Extremely Low Birth Weight; | 2014 |
The role of ischemia in necrotizing enterocolitis.
Topics: Age of Onset; Biomarkers; Enterocolitis, Necrotizing; Glucose Transporter Type 1; Humans; Hypoxia; H | 2016 |
Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants.
Topics: Canada; Cerebral Intraventricular Hemorrhage; Databases, Factual; Enteral Nutrition; Female; Gestati | 2017 |
Antenatal indomethacin is more likely associated with spontaneous intestinal perforation rather than NEC.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enterocolitis, Necrotizing; Humans; Indomethacin; Intestina | 2008 |
Indomethacin-induced colon perforation in Bartter's syndrome.
Topics: Adult; Amniotic Fluid; Anti-Inflammatory Agents, Non-Steroidal; Bartter Syndrome; Colonic Diseases; | 2009 |
Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Drug Administrati | 2010 |
Multiple indomethacin-induced colonic perforations in an adolescent.
Topics: Abdomen, Acute; Administration, Oral; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colectomy | 2011 |
Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Developmental Disabilities; Ductus Arteriosus, Paten | 2013 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Are localized intestinal perforations distinct from necrotizing enterocolitis?
Topics: Adult; Catheterization; Dexamethasone; Diagnosis, Differential; Enterocolitis, Necrotizing; Female; | 2003 |
Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus.
Topics: Birth Weight; Cardiac Surgical Procedures; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteroc | 2003 |
[Indomethacin-induced ileal perforation].
Topics: Aged; Humans; Ileal Diseases; Indomethacin; Intestinal Perforation; Male; Middle Aged | 2004 |
Degos' disease mimicking vasculitis.
Topics: Abdominal Pain; Diagnosis, Differential; Dipyridamole; Drug Administration Schedule; Fatal Outcome; | 2004 |
Postnatal dexamethasone for lung disease of prematurity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Dexamethasone; Drug Synergism; Drug Therapy, Combina | 2004 |
[Diagnostic image (232). A neonate with bilious vomiting].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bile; Female; Humans; Ileum; Indomethacin; Infant, Newborn; | 2005 |
Weighing statistical certainty against ethical, clinical, and biologic expediency: the contributions of the Watterberg trial tip the scales in the right direction.
Topics: Adrenal Insufficiency; Betamethasone; Bronchopulmonary Dysplasia; Dexamethasone; Drug Synergism; Dru | 2005 |
New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Databases, Factual; E | 2006 |
New insights into spontaneous intestinal perforation using a national data set: (2) two populations of patients with perforations.
Topics: Analysis of Variance; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Sc | 2006 |
Attridge et al. present an analysis of a complex data set, which offers important confirmation of the differences between the clinical presentation of spontaneous intestinal perforations (SIP) and surgical necrotizing enterocolitis (NEC).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Enterocolitis, Necrotizing; Humans | 2006 |
Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates.
Topics: Case-Control Studies; Dexamethasone; Ductus Arteriosus, Patent; Female; Humans; Hypotension; Indomet | 2006 |
New insights into spontaneous intestinal perforation using a national data set (3): antenatal steroids have no adverse association with spontaneous intestinal perforation.
Topics: Case-Control Studies; Drug Administration Schedule; Female; Humans; Incidence; Indomethacin; Infant; | 2006 |
Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience.
Topics: Dexamethasone; Enterocolitis, Necrotizing; Feeding Methods; Female; Humans; Indomethacin; Infant, Ex | 2007 |
Gastrointestinal perforation in very low-birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Enterocolitis, Necrotizing; Female | 2006 |
A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Dexamethasone | 2007 |
Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2008 |
Intestinal perforation associated with osmotic slow release indomethacin capsules.
Topics: Aged; Delayed-Action Preparations; Diverticulum, Colon; Female; Humans; Ileal Diseases; Indomethacin | 1983 |
Intestinal perforation associated with osmotic slow release indomethacin capsules.
Topics: Aged; Delayed-Action Preparations; Humans; Indomethacin; Intestinal Perforation; Male | 1984 |
Gastrointestinal perforation following indomethacin therapy in very low birth weight infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1981 |
Indomethacin-induced lesion modifies contractile activity in rat small intestines.
Topics: Acetylcholine; Animals; Carbachol; Electric Stimulation; Gastrointestinal Motility; Ileal Diseases; | 1995 |
Isolated small bowel perforation following intrauterine treatment with indomethacin.
Topics: Adult; Female; Fetal Diseases; Humans; Ileal Diseases; Indomethacin; Infant, Newborn; Intestinal Per | 1994 |
Possible precursor of diaphragm disease in the small intestine.
Topics: Female; Humans; Ileal Diseases; Indomethacin; Intestinal Perforation; Middle Aged; Ulcer | 1993 |
Indomethacin-associated bowel perforations: a study of possible risk factors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Case-Control Studies; Female; Humans; Indomet | 1999 |
Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants.
Topics: Anti-Inflammatory Agents; Bronchopulmonary Dysplasia; Case-Control Studies; Dexamethasone; Female; H | 1999 |
NSAID-induced small bowel perforation.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Hip Fractures; Humans; Ileal Diseases; Indo | 2001 |
Acute perforation of colonic diverticula associated with short-term indomethacin.
Topics: Acute Disease; Aged; Colon, Sigmoid; Diverticulum, Colon; Female; Humans; Indomethacin; Intestinal P | 1978 |
Intravenous indomethacin therapy.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infusions, P | 1992 |
Localized intestinal perforation following intravenous indomethacin in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Intes | 1989 |
Localized intestinal perforation after intravenous indomethacin in a premature infant.
Topics: Female; Humans; Ileal Diseases; Indomethacin; Infant, Newborn; Infant, Premature; Injections, Intrav | 1986 |
Anti-inflammatory drugs and bowel perforations and haemorrhage.
Topics: Adult; Gastrointestinal Hemorrhage; Humans; Indomethacin; Intestinal Perforation; Intestine, Small; | 1985 |
Intestinal perforation following enteral administration of indomethacin.
Topics: Enteral Nutrition; Female; Humans; Ileum; Indomethacin; Infant, Newborn; Intestinal Perforation | 1985 |
Intestinal perforations after enteral administration of indomethacin in premature infants.
Topics: Humans; Indomethacin; Infant, Newborn; Infant, Premature; Intestinal Perforation | 1986 |
Localized intestinal perforations after enteral administration of indomethacin in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ileal Diseases; Indomethacin; Infant, Low Birth Weight; I | 1985 |
Intestinal perforation associated with indomethacin treatment in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; | 1985 |
What's new in Osmosin and intestinal perforation?
Topics: Aged; Humans; Ileal Diseases; Ileum; Indomethacin; Intestinal Perforation; Ulcer | 1985 |
Synthesis and pharmacology of a novel anti-inflammatory agent, ID-1619.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Capillary Permeability; Chemical Phenomena | 1972 |
Indomethacin-induced intestinal lesions in the rat.
Topics: Administration, Oral; Animals; Antacids; Aspirin; Atropine; Bile Ducts; Bretylium Compounds; Chlorpr | 1970 |
Drug induced ulceration and perforation of the small intestine.
Topics: Adult; Humans; Indomethacin; Intestinal Perforation; Intestine, Small; Male; Middle Aged; Ulcer | 1966 |